Although, current clinical practice treats ER+/PR+/HER2- and ER+/PR-/HER2- breast cancer patients in the same way, our study suggests that the PR- group should be more intensively studied to search for an effective therapy due to its poor prognosis. The gene discussed is PGR; the disease is breast cancer.